Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trastuzumab.

C M Perry1, L R Wiseman

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Trastuzumab effectively treats HER2-positive breast cancer by inhibiting tumor growth. Combination therapy significantly improves survival rates and disease progression compared to traditional treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-alpha-2a: a review of its use in chronic hepatitis C.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Enoxaparin: in the prevention of venous thromboembolism in medical patients.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2004
Same author

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

Drugs·2002
Same author

Amisulpride: a review of its use in the management of schizophrenia.

Drugs·2001
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • HER2 (human epidermal growth factor receptor 2) is overexpressed in 25-30% of breast cancers.
  • Trastuzumab is a targeted therapy, a monoclonal antibody against HER2.

Purpose of the Study:

  • To evaluate the efficacy and safety of Trastuzumab in HER2-positive metastatic breast cancer.
  • To compare combination therapy with Trastuzumab plus chemotherapy versus chemotherapy alone.

Main Methods:

  • Phase III clinical trial involving 469 patients with HER2-positive metastatic breast cancer.
  • Patients received Trastuzumab alone or in combination with chemotherapy (paclitaxel or doxorubicin/epirubicin plus cyclophosphamide).

Main Results:

  • Trastuzumab monotherapy showed objective responses in 21% of patients.

Related Experiment Videos

  • Combination therapy demonstrated a higher response rate (49%) and significantly improved median overall survival (25.4 months) compared to chemotherapy alone (20.3 months).
  • Common adverse events included chills, fever, and nausea; cardiac dysfunction was the most serious concern, particularly with combination therapy.

    • Conclusions:

    • Trastuzumab is an effective treatment for HER2-positive metastatic breast cancer.
    • Combination therapy with Trastuzumab offers significant survival benefits over chemotherapy alone.
    • Trastuzumab is generally well-tolerated, but cardiac function requires monitoring.